Detection of Drug Induced Torsades de Pointes Arrhythmia Mechanisms Using hiPSC-CM Syncytial Monolayers in a High Throughput Screening Voltage Sensitive Dye Assay.
We validated three distinct hiPSC-CM cell lines-each of different purity and a voltage sensitive dye based high throughput proarrhythmia screening assay as a non-core site in the recently completed CiPA Myocyte Phase II Validation Study. Blinded validation was performed using 12 drugs linked to low, intermediate or high risk for causing Torsades de Pointes (TdP). Commercially sourced hiPSC-CMs were obtained either from Cellular Dynamics International (CDI, Madison WI, iCell® Cardiomyoyctes2) or Takara Bio (CLS, Cellartis® Cardiomyocytes). A third hiPSC-CM cell line (MCH, Michigan) was generated in house. Each cell type had distinct baseline electrophysiological function (spontaneous beat rate, action potential duration and conduction velocity) and drug responsiveness. Use of voltage sensitive dye and optical mapping enabled the detection of conduction slowing of sodium channel blockers (quinidine, disopyramide and mexiletine) and drug induced TdP like activation patterns (rotors) for some high and intermediate risk compounds. Low risk compounds did not induce rotors in any cell type tested. These results further validate the utility of hiPSC-CMs for predictive proarrhythmia screening and the utility of voltage sensitive dye technology to detect drug induced APD prolongation, arrhythmias (rotors) and conduction slowing. Importantly, results indicate that different ratios of cardiomyocytes and non-cardiomyocytes have important impact on drug response that may be considered during risk assessment of new drugs. Finally, we present the first blinded CiPA hiPSC-CM validation results to simultaneously detect drug induced conduction slowing, action potential duration prolongation, action potential triangulation and drug induced rotors in a proarrhythmia assay.